DigitalBDinc

We use AI to uncover what is really happening in US markets. Math, statistics and probability are our true north.

[DigitalBDinc @DigitalBDinc]

$CDZI Financial News https://t.co/QtYJEAzPLW

Squeeze starts at $5.18 https://t.co/BRsstj5C4U

Funding agreement for evaluation of Mojave Groundwater Bank https://t.co/r2VvpXVHVW

Path to profitability https://t.co/fe7sd6UGVw

Declares quarterly dividend for Q1 2026 Series A https://t.co/H5nYlEf6e9

Selected to submit application for $194M WIFIA loan https://t.co/Z1KYYgUEiO

Investor update https://t.co/CtuXBZggTj

Q3 results https://t.co/CtuXBZggTj

B. Riley $15.00 PT https://t.co/767xQGfzSW

Roth/MKM $10.00 PT https://t.co/muO0DUMfwJ

$51M 1st tranche of up to $450M for Mojave Groundwater Bank project https://t.co/2GALm53uJn

Cadiz to provide perchlorate treatment to support Cactus Basins Recharge Program https://t.co/VIMZ0KZ3il

Signs 2nd MOU for hydrogen-solar development at Cadiz Ranch https://t.co/BgBZvMGU2b

Nation's largest tribal-led water project https://t.co/ucirQRP2fX

Highlighted in Los Angeles Business Journal https://t.co/McgatKSDqC

Twice the fresh water volume of Lake Mead https://t.co/VrBKMNlwFV

Deck https://t.co/pKxJ2WvfB3

Web https://t.co/rzQvO5MMRE

Publicity for this report paid for by third party.

[DigitalBDinc @DigitalBDinc]

@Cadiz_Inc Squeeze imminent. Future of water is clean and affordable. On clear path to profitability. Analysts forecast breakeven in 2 years, projected US$45M profit in 2028 with strong 59% avg annual growth. Delivering innovative water solutions. Links in thread

[DigitalBDinc @DigitalBDinc]

$GNPX Financial News https://t.co/lc5vZzzyls

Positive clinical data on biomarkets in patients receiving Reqorsa Gene Therapy https://t.co/IZILMwO466

Presents positive preclinical data on Type 2 diabetes gene therapy at ASGCT https://t.co/YPppQqkc7O

Patent granted https://t.co/EeElY8kkya

Presents positive preclinical data on Reqorsa gene therapy at AACR https://t.co/Xh8Q1E5rlL

To present positive pre-clinical data on Reqorsa gene therapy for lung cancer at AACR annual meeting https://t.co/dgzEQsXWaU

Reqorsa patent grants in Japan and Europe https://t.co/ShMEC1EibZ

Reverse split leaves only 9M shares issued. Low float and heavily shorted. Split adjusted data here https://t.co/iU4q9TwyYP

AI report identifies up to 30X undervaluation https://t.co/S0BKf22k5X

Positive preliminary preclinical data in Type 2 diabetic animal study of GPX-002 https://t.co/nolDYiuB4X

8-K filing shows Company believes it has the stockholder's equity from recent raises to meet NASDAQ mininmum listing requirements https://t.co/oTXo3jGE86

Adds clincial trial site for Acclaim-1 and Acclaim-3 lung cancer trials https://t.co/m7ZhkFh7gS

Acclaim-1 Phase 1 gene therapy clinical trial data published in Clinical Lung Cancer journal https://t.co/JJv8gKXnaw

Positive preclinical data on use of Reqorsa gene therapy for lung cancer https://t.co/xwbYb8NnjB

Patent issued for Requorsa combined with PD-L1 antibodies https://t.co/8wZ6FwZ6Up

European patent office intent to grant patent for combination of Reqorsa gene therapy and PD-1 antibodies https://t.co/pTywvfA03e

Deck https://t.co/8tFCXDlRvw

Web https://t.co/2oleEViKZw

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@genprex Positive biomarker data published (Trop-2 H-scores 100+, PTEN scores below 100). Encouraging Type 2 diabetes gene therapy. Demonstrates in vivo proof-of-concept for novel diabetes gene therapy. Rejuvenated exhausted beta cells and normalized glucose levels. See links:

[DigitalBDinc @DigitalBDinc]

$WGRX Financial News https://t.co/C5rASVJYfr

Q1 results https://t.co/zRMWKUxSow

Accelerates digital health expansion https://t.co/ndznKX02wS

Pilot MSO collaboration with Kare PharmTech targeting $14B CCM and RPM services market https://t.co/G0bqMuDiPE

Joint venture with Kare PharmaTech https://t.co/cMLSi75PQ0

Shorts exposed https://t.co/sB69Cbj2V3

Report https://t.co/zefqrrL4ND

Squeeze starts at $0.61 https://t.co/uoI3BKI1Kj

Shareholder Letter https://t.co/sX0k2GJeav

Targets $70B market addressing muscle loss from weight loss therapies https://t.co/PBsusgOMiT

Fact Sheet https://t.co/u4LOxozqG4

Deck https://t.co/6xBaHsGS69

Web https://t.co/lcAZ8DhDvZ

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@WGRX_Health Q1 revs near $1M with Q2 guidance of $1.77M . Expands direct sales with focus on $70B market for muscle loss from glp weight loss products. Kare joint venture expands access to 200,000+. EinsteinRx Ai platform optimizes dispensing and patient outcomes. Links below:

[DigitalBDinc @DigitalBDinc]

$RIME Financial News https://t.co/a8tZGT9LCo

Expanded contract with P&G India https://t.co/U2L5oUVGwh

Record Q1 results. Revs +71% from last quarter and +1,851% YOY https://t.co/zlLd4GMt5x

$12M annualized revenue run rate https://t.co/d392jl8xOx

45.65% of all trading volume is short selling. Squeeze starts at $1.99 https://t.co/AlVSV4Qvdu

SemiCab whitepaper https://t.co/LdOygG0vIx

Deck https://t.co/4ZbYzVMhcv

Web https://t.co/Vyogdxplzz

Publicity for this report paid for by the Company

[DigitalBDinc @DigitalBDinc]

@Algorhythm_AI Q1 results are off to a strong start with first quarter revenue growing more than 71% sequentially and more than 1,800% year-over-year as SemiCab business continues to scale. Apex SaaS platform positioned strong growth. Links in thread:

[DigitalBDinc @DigitalBDinc]

$NXXT Financial News https://t.co/6ZWE9ontYt

Q1 earnings call today at 9am EDT https://t.co/8X9n4uApG9

Q1 results. Revs +29% YOY to $21.1M, gross profit more than tripled and interest expense decreased by 80% YOY https://t.co/oSqehlzf5y

One of most promising renewable energy stories https://t.co/c2xPnPgyGd

Launches one of nation's largest last-mile mobile fuel delivery stations https://t.co/QPopPx9lZd

Ai-driven dashboard for integrated energy ecosystem https://t.co/jKocUpOPlD

Expands fleet in highest-margin markets and advances microgrid pipeline https://t.co/66Q3tMkPeT

Ai Deep Research Report with $6.30PT https://t.co/Z6gCV4YHW3

Simply Wallst report with $5.50PT https://t.co/Xyw631jlTl

48% of all trading volume shorted. Squeeze starts at $2.04 https://t.co/C6JZmsUoBV

NeutronX partnership focuses on federal energy and defense infrastructure projects https://t.co/ODda19pEMb

Microgrid operating model https://t.co/hl5macd0mU

Power generation, storage, electronics and software working together to power microgrids https://t.co/H7Hui2HrMq

Deck https://t.co/1xaUCZa4AV

Web https://t.co/uaj5QleX75

Publicity for this report paid for by the Company

[DigitalBDinc @DigitalBDinc]

@NextNRGinc Q1 results. $21.1M in revs, gross profit triples. Earnings call today at 9am EDT. Ai-powered microgrids respond to disruptions and offer autonomous distributed balanced generation while optimizing for cost and resilience. Links below:

[DigitalBDinc @DigitalBDinc]

$JSDA Financial News https://t.co/VZDqWQju3L

Q1 results. Revs $12.4M (+194% yoy), gross profit +179% to $3.9M. Raises 2026 full year revenue guidance to $40M+ https://t.co/A8CnM5wJU6

Expands product offerings in 650 top-volume stores nationwide https://t.co/AknaQkQlho

Expands Canadian distribution through 700 Circle K stores https://t.co/oj8S0vPOJF

Expands Fallout beverage platform with national club store rollout https://t.co/4xLARXK08j

Expanded Costco program increases Q4 momentum https://t.co/aEQj8vWexk

Squeeze starts at $0.74 https://t.co/4lCvndyNMp

Shorts exposed https://t.co/23AAbywroS

Report https://t.co/GfgJyv853M

Bolsters C-Suite with proven business leaders https://t.co/i3P8MgDP9G

Fallout-themed Vault-Tec Supply Packs at select Costco Warehouse Clubs https://t.co/uJAqrhqKkE

Expands in Southeast with additional Costco launch https://t.co/GAyOJ5VuXg

Web https://t.co/vWqgMOEps1

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@jonessodaco Q1 results. Revs $12.4M (+194% yoy), gross profit +179% to $3.9M. Raises 2026 full year revenue guidance to $40M+. Expands Costco , CircleK and Walmart national and international distribution. Squeeze starts at $0.74. Links below:

[DigitalBDinc @DigitalBDinc]

$GTBP Financial News https://t.co/XCvjCQWJsF

Q1 results https://t.co/An1qB8PDOz

1st patient dosed in Phase 1 trial of GTB-5550, a B7-H2 targeted NK cell engage for solid tumors https://t.co/3CsvEy6Nwx

Full year 2025 results https://t.co/qIZtLiQAPe

FDA clearance of IND application for GTB-5550 https://t.co/r02MVlHNpG

Advances Phase I trials https://t.co/LPNDjCbabD

Q3 results https://t.co/mz3tOKNSTD

GTB-3650 advances Phase 1 trial to Cohort 4 following safety review of Cohort 3 https://t.co/STWDcmefX4

Reports progress in Phase 1 trial of lead candidate for blood cancers https://t.co/SJZQqFyYdi

Shorts exposed https://t.co/1R1mUlhUgw

Ai-powered Deep Research report $15.00 PT https://t.co/F5n5LvGztI

Roth/MKM $11.00 PT https://t.co/BTLrpqUhQO

Deck https://t.co/wr6NLcmEN8

Web https://t.co/XVywECRFpK

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@GTBiopharma 1st human dosing. Advances 3 TriKE candidates. Platform combines precision, potency, and potential for fewer side effects than conventional treatments. GTB-3650 Phase 1 for AML/MDS hits Cohort 4 at 10µg/kg—no safety issues. Oncology market $139B-$268B by 2034. Links

[DigitalBDinc @DigitalBDinc]

$GTBP Financial News https://t.co/XCvjCQWJsF

1st patient dosed in Phase 1 trial of GTB-5550, a B7-H2 targeted NK cell engage for solid tumors https://t.co/3CsvEy6Nwx

Full year 2025 results https://t.co/qIZtLiQAPe

FDA clearance of IND application for GTB-5550 https://t.co/r02MVlHNpG

Advances Phase I trials https://t.co/LPNDjCbabD

Q3 results https://t.co/mz3tOKNSTD

GTB-3650 advances Phase 1 trial to Cohort 4 following safety review of Cohort 3 https://t.co/STWDcmefX4

Reports progress in Phase 1 trial of lead candidate for blood cancers https://t.co/SJZQqFyYdi

Shorts exposed https://t.co/WFh8xhHIoM

Ai-powered Deep Research report $15.00 PT https://t.co/F5n5LvGztI

Roth/MKM $11.00 PT https://t.co/BTLrpqUhQO

Deck https://t.co/wr6NLcmEN8

Web https://t.co/XVywECRFpK

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@GTBiopharma $GTBP 1st human dosing. Advanced TriKE next-generation platform combines precision, potency, and potential for fewer side effects than conventional treatments. GTB-3650 Phase 1 for AML/MDS hits Cohort 4 at 10µg/kg—no safety issues. Oncology market $139B-$268B by 2034

[DigitalBDinc @DigitalBDinc]

$NXPL Financial News https://t.co/bGYQz8MiaE

$9.9 Million in Revenue for Q1 2026 with Record Quarterly Consolidated Gross Margins of 35% https://t.co/akYWEh0QzZ

Expects Q1 gross margins to jump to 34%+ https://t.co/j9ylQVkF4V

Regains full NASDAQ compliance https://t.co/7oKW3CUJ1N

Deploys PharmcoRX AI-powered presciption processing https://t.co/XzTiF0UQ18

$400k IoT contract brings military Q1'26 pipeline to $1.2M https://t.co/5UdweGPYu3

Full year earnings results https://t.co/Ph6W7r74wb

Launches 50 state nationwide fulfillment capabilities https://t.co/DJpdl1LjyA

$820,000 Global Telesat contract award https://t.co/2sXnnFLZsS

Expects $55M in 2025 revenues and higher margins in 2026 https://t.co/GzFcwoPMyL

Shorts exposed https://t.co/zdEW2bVFwb

Report https://t.co/bxxbFP1M2h

Squeeze starts at $13.52 https://t.co/PdZr0XVP5l

International expansion https://t.co/FW734B9WFH

Expands 5G and AI powered IOT through new Telit Cinterion agreement https://t.co/LWjNBVsWSG

Deck https://t.co/AwrlnDNIHk

Web https://t.co/mmtzSRqQ1s

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@nextplat Q1 revs $9.9M with record 35% gross margins vs 21% in prior year. Reduces expenses 9%. Expects positive net income in 2nd half. $54.3M full year 2025 revs, 340B covered entities, higher margin fulfillment exceeding 6,000+ scripts per month. Links below:

[DigitalBDinc @DigitalBDinc]

$MBRX Financial News https://t.co/pE8CRb4ACN

MIRACLE Trial unblinding imminent as blinded data continues to significantly outperform historical benchmarks https://t.co/C3R6ISCsAn

Cleveland Clinic finds no clinically significant cardiotoxicity with Annamycin in R/R AML patients https://t.co/hFnZdTxdSE

Secures additional strategic patent https://t.co/1iaJzyvbxG

Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5

Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp

Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw

FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D

Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R

Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c

Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo

Shorts exposed https://t.co/wfr1PKBx5M

Deck https://t.co/C8eZhu7phl

Web https://t.co/EPK7T2Bnsx

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@moleculinbio Trial unblinding imminent. ClevelandClinic finds no significant cardiotoxicity. Extends survival by more than 60% in metastatic pancreatic cancer pre-clin models. If mid '26 results of 45 person cohort confirms 40% CRc rate, risk drops. Links below:

[DigitalBDinc @DigitalBDinc]

$WGRX Financial News https://t.co/C5rASVKw4Z

Pilot MSO collaboration with Kare PharmTech targeting $14B CCM and RPM services market https://t.co/G0bqMuDQFc

Joint venture with Kare PharmaTech https://t.co/cMLSi76nFy

Shorts exposed https://t.co/sB69CbjAKB

Report https://t.co/zefqrrLCDb

Squeeze starts at $0.89 https://t.co/fVMXZGgIMa

LOI to potentially acquire Neuritek Therapeuics for $105M https://t.co/RvPtGOyJZq

Shareholder Letter https://t.co/sX0k2GJM03

Targets $70B market addressing muscle loss from weight loss therapies https://t.co/PBsusgPk8r

Fact Sheet https://t.co/u4LOxozYvC

Deck https://t.co/6xBaHsHpVH

Web https://t.co/lcAZ8Diblx

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@WGRX_Health Targets $14B market with new collab. Kare joint venture expands access to 200,000+. $105M letter of intent to acquire Neuritek. Targets $70B market for muscle loss due to weight loss products. EinsteinRx Ai platform to optimize dispensing and patient outcomes. Links

[DigitalBDinc @DigitalBDinc]

$MBRX Financial News https://t.co/pE8CRb4ACN

MIRACLE Trial unblinding imminent as blinded data continues to significantly outperform historical benchmarks https://t.co/C3R6ISCsAn

Cleveland Clinic finds no clinically significant cardiotoxicity with Annamycin in R/R AML patients https://t.co/hFnZdTxdSE

Secures additional strategic patent https://t.co/1iaJzyvbxG

Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5

Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp

Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw

FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D

Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R

Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c

Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo

Shorts exposed https://t.co/IgXIFrtolr

Deck https://t.co/C8eZhu7phl

Web https://t.co/EPK7T2Bnsx

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@moleculinbio Trial unblinding imminent. @ClevelandClinic finds no significant cardiotoxicity. Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models. If mid '26 results of 45-patient cohort confirms 40% CRc rate, clinical risk drops.

[DigitalBDinc @DigitalBDinc]

$MBRX Financial News https://t.co/pE8CRb4ACN

Secures additional strategic patent https://t.co/1iaJzyvbxG

Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5

Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp

Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw

FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D

Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R

Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c

Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo

Shorts exposed https://t.co/IgXIFrtolr

Deck https://t.co/C8eZhu7phl

Web https://t.co/EPK7T2Bnsx

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@moleculinbio Secures additional strategic patent. Solid intellectual property protection globally ahead of pending Phase 3 data release. Links below:

[DigitalBDinc @DigitalBDinc]

@moleculinbio $MBRX Financial News https://t.co/pE8CRb4ACN

Secures additional strategic patent https://t.co/1iaJzyvbxG

Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5

Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp

Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw

FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D

Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R

Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c

Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo

Shorts exposed https://t.co/IgXIFrtolr

Deck https://t.co/C8eZhu7phl

Web https://t.co/EPK7T2Bnsx

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

Secures additional strategic patent. Solid intellectual property protection across four continents ahead of pending Phase 3 data release. Links below:

[DigitalBDinc @DigitalBDinc]

@moleculinbio $MBRX Financial News https://t.co/pE8CRb4ACN

Secures additional strategic patent https://t.co/1iaJzyvbxG

Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5

Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp

Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw

FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D

Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R

Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c

Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo

Shorts exposed https://t.co/IgXIFrtolr

Deck https://t.co/C8eZhu7phl

Web https://t.co/EPK7T2Bnsx

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

$MBRX Financial News https://t.co/pE8CRb4ACN

Secures additional strategic patent https://t.co/1iaJzyvbxG

Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5

Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp

Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw

FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D

Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R

Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c

Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo

Shorts exposed https://t.co/IgXIFrtolr

Deck https://t.co/C8eZhu7phl

Web https://t.co/EPK7T2Bnsx

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@moleculinbio Secures additional strategic patent. Solid intellectual property protection across four continents ahead of pending Phase 3 data release. Links below:

[DigitalBDinc @DigitalBDinc]

$MBRX Financial News https://t.co/pE8CRb4ACN

Secures additional strategic patent https://t.co/1iaJzyvbxG

Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5

Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp

Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw

FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D

Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R

Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c

Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo

Shorts exposed https://t.co/IgXIFrtolr

Deck https://t.co/C8eZhu7phl

Web https://t.co/EPK7T2Bnsx

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

Secures additional strategic patent. Annamycin extends survival by more than 60% in metastatic pancreatic cancer models. If mid '26 unblinding of 45-person cohort confirms 40% CRc rate, risk drops. Links below:

[DigitalBDinc @DigitalBDinc]

$CRDL Financial News https://t.co/oeVyN1Wixn

Phase 2 Maveric results accepted for publication in Journal of American Heart Association https://t.co/7c7nDkW7cW

Expands MAVERIC Phase III trial in the US https://t.co/LGLvDBwGre

CardiolRx shows Myocarditis promise https://t.co/hDBaQylEKg

Squeeze starts at $1.39 https://t.co/mGXiiAy4iY

Canaccord $8.00 PT https://t.co/LTfaaMauNM

FY 2025 results https://t.co/QPmHnbxRqT

ARCHER Phase 2 study results published in ESC Heart Failure https://t.co/5Y6YIqg1x2

50% enrollment in Phase 3 MAVERIC trial in recurrent pericarditis https://t.co/qC5rmOELNL

Leede $11.00PT https://t.co/iN5Hd1CuV2

Roth $10.00PT https://t.co/OJPQwlWd84

HC Wainwright $9.00PT https://t.co/jyf2M5w5H8

Deck https://t.co/jqJxbxLEi2

Web https://t.co/LWdxchpieP

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@CardiolRx Phase 2 Maveric results accepted for publication in JAHA. Expands Phase 3 trial network. Positive Phase 2 Archer data in acute myocarditis. Advances CRD-38 program, a novel next generation therapy intended for use in heart failure. Broad patents. See links

[DigitalBDinc @DigitalBDinc]

$AMZE Financial News https://t.co/u0o0bznYRX

Partners with All Media Solutions to power brand supply for Amaze Live https://t.co/A5FhmqoyFR

LOI with Digital Innovations to integrate IRMA engine to expand creator and fan monetization https://t.co/dSTHGbKWTv

20 brands commit inventory to Amaze Live shopping https://t.co/QFIjYVwjMk

Launches next-generation multi-channel live shopping platform https://t.co/GXqMFIUGln

Get early access to Amaze Live shopping https://t.co/NUCZJq35hg

Launches Creator Commerce media platform https://t.co/17zlqe2T7D

Previews new product launch of Amaze Commerce https://t.co/mzJ4C81HLH

Shareholder update https://t.co/bbCcYIF82A

Amaze and LA Times Studios launch Food Channel LA, a creator-led commerce platform https://t.co/g5ZcsViyd5

Shorts exposed https://t.co/SowmjOJBNk

Report https://t.co/rQ0yWRi9Mk

Ladenburg Thalmann $3.00PT https://t.co/clBL063HXI

Squeeze starts at $1.04 https://t.co/C76j7UTdWt

Investor Summit presentation March 25th 9am EDT https://t.co/XLOx7oMIbJ

Expanded live shopping capabilities for creators https://t.co/EkBAHzyyb7

Launches proprietary programmtic advertising platform https://t.co/Tx1A16Xplz

Partners with https://t.co/74gsEWexXs to provide customizable Plushies for creators https://t.co/iF3RsXAJJe

Deck https://t.co/MgUj5JUYCO

Web https://t.co/m5PD9Vxfu8

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

Amaze partners with All Media Solutions for live shopping. Announces Creator Commerce media platform. Billions of visits and millions of stores, data has become key value creator. Launches creator-led Food Channel commerce platform with @LATimes. Links below:

[DigitalBDinc @DigitalBDinc]

THREAD

$XXII Financial News https://t.co/gVENVi0B1i

2026 vision for VLN product growth https://t.co/i7I45BQ3VT

New testing services agreement https://t.co/xLfh3SZamr

Targets half of $82B US market with 100mm VLN product initiative https://t.co/vdW1xHKxoN

Q4 results https://t.co/WPolZztgif

Shorts exposed https://t.co/sOx5omLA3i

Only combustible product authorized by FDA to specifically address cessation https://t.co/z4IHbksLZL

Emerging Growth issues updated report https://t.co/0cvAUKmnRZ

Emerging Growth report $9.00PT https://t.co/HCc2rEYcUF

Secures $9.5 million in proceeds from insurance claim settlement https://t.co/0tWaAn2uaD

Debt free balance sheet and new growth capital https://t.co/W5RDYzFjsj

Growing list of state authorizations https://t.co/RMd963V9Cl

Multiple brands partner to expand availability and awareness of VLN products https://t.co/y7deO9JZiw

Deck https://t.co/VG9aSW6dfR

Publicity for this report paid for by the Company.

[DigitalBDinc @DigitalBDinc]

@_xxiicentury Corporate update outlines vision for low nic alternative. Multiple scientific studies demonstrate merits of products. Non-addictive alternative in the fight against the harms of inhaled combustibles. Links in thread: